Tissue factor (F3) gene variants and thrombotic risk among middle-aged and older adults: a population-based cohort study

Abstract

BackgroundTissue factor (TF), encoded by the F3 gene, is the main initiator of blood coagulation. The molecular epidemiology of the F3 gene and the relation to venous thromboembolism (VTE) remains to be determined. ObjectivesThe aim was to determine the molecular epidemiology and the importance of F3 variants for incident VTE by analysis of the population-based MDC study (Malmö Diet and Cancer), consisting of unselected middle-aged and older individuals. MethodsThe exons of F3 were analyzed in a total of 28,794 individuals from the MDC cohort, and of these, 2584 (9%) were affected by VTE during follow‐up (1991-2018). Qualifying variants used in gene-collapsing analysis were defined as loss-of-function or non-benign (PolyPhen-2) missense variants with minor allele frequency less than 0.1%. ResultsExon sequencing of the F3 gene identified 61 different variants, 3´ UTR variants (n=5), 5´ UTR variants (n=9) synonymous (n=10), in frame insertion (n=1), splice region variants (n=2), missense (n=33) or loss-of-function variants (n=1). No associations between common F3 gene variants and incident VTE were found. Seventeen rare variants were classified as qualifying and included in collapsing analysis (16 non-benign missense and 1 loss-of-function variants). The prevalence of F3 qualifying variants was 0.14%. Seven individuals with F3 qualifying variants had VTE, while 34 individuals had no VTE. The adjusted VTE model was significant (hazard ratio=2.1 [95% confidence interval, 1.02–4.48], P-value=0.045). ConclusionsQualifying F3 gene variants are very rare, indicating a constrained gene. Rare but not common variation in the F3 gene may be involved in VTE.